Working collaboratively with Protean BioDiagnostics, Inc. to offer the Endocrine Activity IndexTM (EAITM) will allow Delphi Diagnostics to expand the ability to participate in additional clinical trials, as well as begin an Early Access Program in the first half of 2024.
Houston, TX, April 2, 2024 – Delphi Diagnostics, Inc. announces a strategic partnership with Protean BioDiagnostics, Inc. to offer the Endocrine Activity IndexTM also known as EAITM. Protean BioDiagnostics is headquartered in Orlando Florida and is a CAP/CLIA-accredited, high-complexity laboratory specializing in developing and commercializing advanced cancer diagnostic technologies. This collaboration will allow Delphi to expand the ability to participate in additional clinical trials, as well as begin an Early Access Program in the first half of 2024.
“Today, many breast cancer patients experience adverse effects from routinely prescribed adjuvant therapies because current tests do not provide all the information required for optimal personalized treatment decisions. Delphi Diagnostics seeks to change this with the Endocrine Activity Index™ (EAI),” said Winz Casagrande, Chief Executive Officer of Delphi Diagnostics. “This collaboration with Protean will allow Delphi to take a meaningful step forward in our mission of bringing EAI to breast cancer patients and opening new pathways for personalized breast cancer treatment.”
EAI can provide actionable information for prognosis and prediction of chemotherapy benefits. The EAI test has been shown in various studies to be a consistent prognostic indicator for long-term outcomes in HR+HER2- stage II-III breast cancer patients. The EAI results add prognostic information that is independent of any other test currently on the market. Most recently, EAI has been shown to be predictive for response to dose-dense chemotherapy (ddAC-T) in the CALGB 9741 trial.1
Anthony M. Magliocco, MD, FRCPC, FCAP, Protean’s President and CEO, added, “Working with Delphi to offer EAI aligns well with our mission to improve access to precision cancer diagnostics for all patients. We are excited about the opportunity to expand Delphi’s capacity to participate in clinical trials, further developing its portfolio of clinical evidence behind EAI. Through this collaboration, we will also be leveraging Protean’s ability to develop and deploy the latest and highest quality laboratory tools by kicking off an Early Access Program, a first step in offering EAI outside clinical trials and direct to physicians and their patients.”
The collaboration between Protean and Delphi brings together laboratory expertise with leading-edge technology, leveraging the strengths of both organizations to help scale quickly and bring the Endocrine Activity Index to breast cancer patients, allowing providers to practice precision medicine.
*EAI is known in scientific publications as the Sensitivity to Endocrine Therapy (SET) Test.
- Metzger, Otto et al. Measurement of endocrine activity (SET2,3) related to prognosis and prediction of benefit from dose-dense (DD) chemotherapy in estrogen receptor-positive (ER+) cancer: CALGB 9741 (Alliance). 2022 American Society of Clinical Oncology Annual Meeting, Chicago, IL. June 3-7, 2022. https://meetings.asco.org/abstracts-presentations/208274
About EAI
Delphi Diagnostics test, the Endocrine Activity Index™ (EAI) can provide actionable information for prognosis and prediction of chemotherapy benefits. The EAI measures endocrine activity in stage II-III, HR+HER2- breast cancer. The Index Score is adjusted for baseline prognosis using molecular subtype genes (RNA4) and clinical factors such as tumor size and regional lymph node involvement. The EAI test has been shown in various studies to be a consistent prognostic indicator for long-term outcomes in stage II-III breast cancer patients, be independent of other prognostic tests, as well as be predictive for response to dose-intense chemotherapy.
About Delphi Diagnostics
Delphi Diagnostics Inc. is a Texas-based company focused on advancing clinically valid tests for the prognosis and prediction of breast cancer treatment. Delphi Diagnostics, Inc. holds an exclusive license from The University of Texas MD Anderson Cancer Center in Houston, TX to commercialize the Endocrine Activity Index, a technology that was developed by the laboratory of Dr. W. Fraser Symmans**. The Endocrine Activity Index (EAI) test measures endocrine activity in stage II-III, HR+HER2- breast cancer. Delphi’s vision is to make the EAI test available to breast cancer patients and open new pathways for personalized breast cancer treatment. To learn more, visit www.delphi-diagnostics.com.
**Dr. Symmans has a personal financial relationship with Delphi that has been identified as a conflict of interest with this research and is managed by MD Anderson’s Conflict of Interest Committee.
Contact Delphi Diagnostics:
Emily Granger
Delphi Diagnostics Inc.
egranger@delphi-diagnostics.com
508.341.9331
About Protean BioDiagnostics Inc.
Protean BioDiagnostics Inc. is bringing precision care diagnostics to all patients, everywhere, through its innovative Protean MAPS™ platform with integrated Virtual Tumor Boards. In addition, Protean assists world-class pharmaceutical and biotech companies in developing clinical assays and companion diagnostics from its CLIA-certified, CAP-accredited laboratory in Orlando, FL. To learn more visit www.proteanbiodx.com.
Contact Protean BioDiagnostics:
Anthony Magliocco MD
813-817-2042
magliocco@proteanbiodx.com